Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2016

18.03.2016 | Original Article

Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy

verfasst von: Ales Groselj, Mojca Krzan, Tina Kosjek, Masa Bosnjak, Gregor Sersa, Maja Cemazar

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

With the aim to determine effective therapeutic window of electrochemotherapy, we analyzed bleomycin pharmacokinetic parameters in elderly patients.

Methods

In prospective clinical study in the treatment of tumors with electrochemotherapy, blood samples of patients older than 65 years were collected after the bolus intravenous injection of bleomycin (15,000 IU/m2). In serum samples, quantitative analysis was performed with liquid chromatography coupled to high-resolution mass spectrometry. Based on the data, the pharmacokinetic parameters of bleomycin elimination were determined.

Results

Pharmacokinetic analysis of the data revealed a monophasic serum clearance curve, which demonstrates slow elimination of bleomycin, being less than 500 ml/min and a half-time of 30 min.

Conclusions

Slow monophasic elimination of bleomycin from serum in elderly patients implies on the longer therapeutic window, from 8 to up to 40 min or even longer post-bleomycin injection for electrochemotherapy. However, prolonged therapeutic bleomycin serum concentrations may also affect the possible adverse effects, such as lung fibrosis and extensive necrosis of tumors due to the uptake of toxic bleomycin concentrations into the tumors. This may imply on lowering of bleomycin dosage, in particular in the elderly patients.
Literatur
3.
Zurück zum Zitat Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J, Mir LM (1999) Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57:45–56. doi:10.1016/S0006-2952(98)00282-2 CrossRefPubMed Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J, Mir LM (1999) Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57:45–56. doi:10.​1016/​S0006-2952(98)00282-2 CrossRefPubMed
4.
Zurück zum Zitat Sugiura Y, Uesawa Y, Takahashi Y, Kuwahara J, Golik J, Doyle TW (1989) Nucleotide-specific cleavage and minor-groove interaction of DNA with esperamicin antitumor antibiotics. Proc Natl Acad Sci USA 86:7672–7676CrossRefPubMedPubMedCentral Sugiura Y, Uesawa Y, Takahashi Y, Kuwahara J, Golik J, Doyle TW (1989) Nucleotide-specific cleavage and minor-groove interaction of DNA with esperamicin antitumor antibiotics. Proc Natl Acad Sci USA 86:7672–7676CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ferrando AA, Velasco G, Campo E, Lopez-Otin C (1996) Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res 56:1746–1750PubMed Ferrando AA, Velasco G, Campo E, Lopez-Otin C (1996) Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res 56:1746–1750PubMed
7.
Zurück zum Zitat Buxton IO, Benet LZ (2011) Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York Buxton IO, Benet LZ (2011) Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York
8.
Zurück zum Zitat Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB (1981) Pharmacokinetics of bleomycin after im administration in man. Cancer Treat Rep 65:485–489PubMed Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB (1981) Pharmacokinetics of bleomycin after im administration in man. Cancer Treat Rep 65:485–489PubMed
9.
Zurück zum Zitat Bitran JD (1985) Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer 56:2420–2423CrossRefPubMed Bitran JD (1985) Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer 56:2420–2423CrossRefPubMed
10.
Zurück zum Zitat Howell SB, Schiefer M, Andrews PA, Markman M, Abramson I (1987) The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol 5:2009–2016PubMed Howell SB, Schiefer M, Andrews PA, Markman M, Abramson I (1987) The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol 5:2009–2016PubMed
11.
Zurück zum Zitat Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS (1982) Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 9:22–25CrossRefPubMed Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS (1982) Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 9:22–25CrossRefPubMed
13.
Zurück zum Zitat Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23:651–661. doi:10.1111/j.1529-8019.2010.01370.x CrossRefPubMed Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23:651–661. doi:10.​1111/​j.​1529-8019.​2010.​01370.​x CrossRefPubMed
16.
Zurück zum Zitat Domenge C, Orlowski S, Luboinski B, De Baere T, Schwaab G, Belehradek J Jr, Mir LM (1996) Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 77:956–963CrossRefPubMed Domenge C, Orlowski S, Luboinski B, De Baere T, Schwaab G, Belehradek J Jr, Mir LM (1996) Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 77:956–963CrossRefPubMed
17.
Zurück zum Zitat Mir LM, Gehl J, Sersa G, Collins CG, Garbaya JR, Billarda V, Geertsend PF, Rudolf Z, O’Sullivanf GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supp 4:14–25CrossRef Mir LM, Gehl J, Sersa G, Collins CG, Garbaya JR, Billarda V, Geertsend PF, Rudolf Z, O’Sullivanf GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supp 4:14–25CrossRef
18.
Zurück zum Zitat Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, Danceyg J, Arbuckh Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, Lacombec D, Verweijk J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026 CrossRef Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, Danceyg J, Arbuckh Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, Lacombec D, Verweijk J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.​1016/​j.​ejca.​2008.​10.​026 CrossRef
19.
Zurück zum Zitat Groselj A, Kos B, Cemazar M, Urbancic J, Kragelj G, Bosnjak M, Veberic B, Strojan P, Miklavcic D, Sersa G (2015) Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy. Biomed Eng Online 14(Suppl 3):S2. doi:10.1186/1475-925X-14-S3-S2 CrossRefPubMedPubMedCentral Groselj A, Kos B, Cemazar M, Urbancic J, Kragelj G, Bosnjak M, Veberic B, Strojan P, Miklavcic D, Sersa G (2015) Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy. Biomed Eng Online 14(Suppl 3):S2. doi:10.​1186/​1475-925X-14-S3-S2 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Campana LG, Mali B, Sersa G, Valpione S, Giorgi CA, Strojan P, Miklavcic D, Rossi CR (2014) Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 52:957–964. doi:10.1016/j.bjoms.2014.08.004 CrossRefPubMed Campana LG, Mali B, Sersa G, Valpione S, Giorgi CA, Strojan P, Miklavcic D, Rossi CR (2014) Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 52:957–964. doi:10.​1016/​j.​bjoms.​2014.​08.​004 CrossRefPubMed
21.
Zurück zum Zitat Kenakin TP (ed) (2014) Tecniques for more effective and strategic drug discovery. In: A pharmacology primer, 4 edn. Academic Press, San Diego, pp 213–253 Kenakin TP (ed) (2014) Tecniques for more effective and strategic drug discovery. In: A pharmacology primer, 4 edn. Academic Press, San Diego, pp 213–253
22.
Zurück zum Zitat Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE (1983) Bleomycin disposition in children with cancer. Clin Pharmacol Ther 33:668–673CrossRefPubMed Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE (1983) Bleomycin disposition in children with cancer. Clin Pharmacol Ther 33:668–673CrossRefPubMed
23.
Zurück zum Zitat Alberts DS, Chen HS, Woolfenden JM, Moon TE, Chang SY, Hall JN, Himmelstein KJ, Gross J, Salmon SE (1979) Pharmacokinetics of bleomycin in man. III. Bleomycin 57Co Vs bleomycin. Cancer Chemother Pharmacol 3:33–40CrossRefPubMed Alberts DS, Chen HS, Woolfenden JM, Moon TE, Chang SY, Hall JN, Himmelstein KJ, Gross J, Salmon SE (1979) Pharmacokinetics of bleomycin in man. III. Bleomycin 57Co Vs bleomycin. Cancer Chemother Pharmacol 3:33–40CrossRefPubMed
24.
Zurück zum Zitat Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14CrossRefPubMedPubMedCentral Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Fulop T, Worum I, Csongor J, Foris G, Leovey A (1985) Body-composition in elderly people. 1. Determination of body-composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 31:6–14CrossRefPubMed Fulop T, Worum I, Csongor J, Foris G, Leovey A (1985) Body-composition in elderly people. 1. Determination of body-composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 31:6–14CrossRefPubMed
27.
Zurück zum Zitat Cadossi R, Ronchetti M, Cadossi M (2014) Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol 10:877–890. doi:10.2217/fon.13.235 CrossRefPubMed Cadossi R, Ronchetti M, Cadossi M (2014) Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol 10:877–890. doi:10.​2217/​fon.​13.​235 CrossRefPubMed
29.
Zurück zum Zitat Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, Snoj M, Miklavcic D, Gadzijev EM, Sersa G (2014) Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 110:320–327. doi:10.1002/jso.23625 CrossRefPubMed Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, Snoj M, Miklavcic D, Gadzijev EM, Sersa G (2014) Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 110:320–327. doi:10.​1002/​jso.​23625 CrossRefPubMed
30.
Zurück zum Zitat Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109:270–274. doi:10.1002/jso.23481 CrossRefPubMed Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109:270–274. doi:10.​1002/​jso.​23481 CrossRefPubMed
31.
Zurück zum Zitat Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM (1993) Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial. Cancer 72:3694–3700CrossRefPubMed Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM (1993) Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial. Cancer 72:3694–3700CrossRefPubMed
32.
Zurück zum Zitat Mir LM, Tounekti O, Orlowski S (1996) Bleomycin: revival of an old drug. Gen Pharmacol 27:745–748CrossRefPubMed Mir LM, Tounekti O, Orlowski S (1996) Bleomycin: revival of an old drug. Gen Pharmacol 27:745–748CrossRefPubMed
Metadaten
Titel
Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy
verfasst von
Ales Groselj
Mojca Krzan
Tina Kosjek
Masa Bosnjak
Gregor Sersa
Maja Cemazar
Publikationsdatum
18.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3004-z

Weitere Artikel der Ausgabe 5/2016

Cancer Chemotherapy and Pharmacology 5/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.